MediciNova

R&D

The ALS clinical trial landscape is characterised by a significant number of active trials and sponsors, including MediciNova's Ph3 with MN-166.

News

Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.